Today s Technology, Tomorrow s Technology, Tomorrow s Therapy s - - PowerPoint PPT Presentation

▶
today s technology tomorrow s technology tomorrow s
SMART_READER_LITE
LIVE PREVIEW

Today s Technology, Tomorrow s Technology, Tomorrow s Therapy s - - PowerPoint PPT Presentation

Oct 06, 2023 338 likes •610 views

Today s Technology, Tomorrow s Technology, Tomorrow s Therapy s Therapy Today Disclaimer Disclaimer The material contained in this presentation must be considered as general background information on Cygenics Ltd. This s general

slide-1
SLIDE 1

Today Today’ ’s Technology, Tomorrow s Technology, Tomorrow’ ’s Therapy s Therapy

Disclaimer Disclaimer The material contained in this presentation must be considered a The material contained in this presentation must be considered as general background information on Cygenics Ltd. This s general background information on Cygenics Ltd. This presentation does not contain any earning guidance. The informat presentation does not contain any earning guidance. The information presented is in summary form and where indicated ion presented is in summary form and where indicated figures used are unaudited. The information contained in this pr figures used are unaudited. The information contained in this presentation is subject to risks and uncertainties that may esentation is subject to risks and uncertainties that may cause actual results to differ materially from those indicated. cause actual results to differ materially from those indicated. This information should not be relied upon or seen as advice This information should not be relied upon or seen as advice as to investors. Investors should obtain independent professiona as to investors. Investors should obtain independent professional advice. l advice.

slide-2
SLIDE 2

Who we are Who we are

CyGenics is a cell therapy company CyGenics is a cell therapy company focused on the development and focused on the development and commercialisation of adult stem cell commercialisation of adult stem cell related technologies related technologies

slide-3
SLIDE 3

Value proposition Value proposition

Technology + Revenue = Managed risk Technology + Revenue = Managed risk Near term clinical trial results Near term clinical trial results Rapidly growing revenue streams Rapidly growing revenue streams Strong and Global IP position Strong and Global IP position

slide-4
SLIDE 4

1 2 3

Expanded and/or Differentiated Stem Cell Transplant Primary Cell Transplant Chemotherapy / Symptomatic Treatment

Milestones in Medicine Technology Progression

The next medical milestone The next medical milestone

slide-5
SLIDE 5

Cell Therapy market space Cell Therapy market space

Tissue Banking Products & Devices Diagnostics & Theranostics Equipment & Instruments Reagents Support Services Clinical Trials Indications Clinical Therapy Biologics

Value Add

slide-6
SLIDE 6

Company structure & businesses Company structure & businesses

Tissue Banking Products & Devices Diagnostics & Theranostics Equipment & Instruments Reagents Support Services Clinical Trials Indications Clinical Therapy Biologics

Value Add

slide-7
SLIDE 7

Revenue by business Revenue by business – – Tissue Banking Tissue Banking

$257 $893 $1,062 $1,506

$0 $500 $1,000 $1,500 $2,000 FY02 FY03 FY04 FY05

$1 $17 $88 $95

$0 $50 $100 $150 FY02 FY03 FY04 FY05

Cordlife Sign-up Revenue (A$000) Cordlife Annuity Revenue (A$000)

  • Average revenue growth of

30% since FY’03

  • Expansion in new markets to

drive strong revenue growth

  • Substantial increase in FY’06

annuity revenue

  • Average revenue growth of

30% since FY’03

  • Expansion in new markets to

drive strong revenue growth

  • Substantial increase in FY’06

annuity revenue

slide-8
SLIDE 8

$558 $66

$0 $250 $500 $750 $1,000 FY04 FY05

Cell Sciences Revenue (A$000)

Revenue by business Revenue by business – – Products & Devices Products & Devices

  • Strong revenue growth
  • Expansion of product range

to drive strong revenue growth

  • Strong revenue growth
  • Expansion of product range

to drive strong revenue growth

slide-9
SLIDE 9

Revenue by business Revenue by business – – Support Services Support Services

$1,230 $1,124

$0 $500 $1,000 $1,500 $2,000 FY04 FY05

Cytomatrix Revenue (A$000)

  • Current revenue from

annual contracts

  • Revenue growth from
  • ther services
  • Current revenue from

annual contracts

  • Revenue growth from
  • ther services
slide-10
SLIDE 10

Market size & growth Market size & growth

Source : JainPharmaBiotech 2004 edition

$7.8 b $7.8 b $3.7 b $3.7 b $2.5 b $2.5 b

Supporting Supporting technologies: cell technologies: cell lines, cell culture, lines, cell culture, delivery devices delivery devices

$1.3 b $1.3 b $700 m $700 m $200 m $200 m

Cord Blood Cord Blood banking banking

2012 2012 2007 2007 2002 2002 USD$ mil USD$ mil

slide-11
SLIDE 11

Company structure & businesses Company structure & businesses

Tissue Banking Products & Devices Diagnostics & Theranostics Equipment & Instruments Reagents Support Services Clinical Trials Indications Clinical Therapy Biologics

Value Add

slide-12
SLIDE 12

Stem Cell Expansion Technology

Commercialising Commercialising Core Core Technologies Technologies

T cell Production Technology

slide-13
SLIDE 13
  • Insufficient stem cells for most adult transplants
  • 3D scaffold for growth of adult stem

cells -> expanded high quality stem cells

Stem Cell Expansion Stem Cell Expansion

Problem Answer

Expansion

slide-14
SLIDE 14

Stem Cell Expansion Market Stem Cell Expansion Market

151,096 151,096 Non Non-

  • Hodgkin

Hodgkin’ ’s Lymphoma s Lymphoma 358,497 358,497 Total Total 124,202 124,202 Leukaemia Leukaemia 55,166 55,166 Multiple Myeloma Multiple Myeloma 28,033 28,033 Hodgkin Hodgkin’ ’s Lymphoma s Lymphoma Cancers of the I mmune System Incidence in Developed Regions (New Cases Annually)

Source: Data derived from GLOBOCAN 2002 database: summary table (abstracts), International Agency for Research on Cancer (IARC) and CANCERMondial, Descriptive Epidemiology Group (DEP) of IARC

Worldwide (1st World) market size

Potential sales Potential sales $500m annually $500m annually 50,000 potential 50,000 potential kit sales annually kit sales annually 358,000 358,000 potential

potential patients patients (1st world)

(1st world)

Kit Price Kit Price US $10,000 US $10,000

Expansion

slide-15
SLIDE 15

What is a T Cell? What is a T Cell? Type of white blood cell that coordinates the immune system Type of white blood cell that coordinates the immune system Millions of T cells are Millions of T cells are made by our Thymus when young made by our Thymus when young Each T cell targets a specific disease, virus, cancer or bacter Each T cell targets a specific disease, virus, cancer or bacteria ia

360 360 360 360 360 360 400

V β 1 V β 2 V β 3 V β 4 V β 5.1 V β 5.2-3 V β 6.1-3

T cell immunotherapy T cell immunotherapy

T Cells

slide-16
SLIDE 16

Problem

  • T cell generation by the Thymus is limited beyond puberty
  • Gaps in T cell repertoire occur due to:

Aging Infections Treatments

T cell immunotherapy T cell immunotherapy

T Cells

Answer

  • 3D scaffold technology creates artificial thymus
  • Stem cells + Stroma + Cytomatrix ™ new T cells
slide-17
SLIDE 17

Restoration of the human immune system

T cell immunotherapy T cell immunotherapy

T Cells

slide-18
SLIDE 18

T Cell Immunotherapy Market T Cell Immunotherapy Market

1.75 1.75-

  • 1.95 million

1.95 million 70,000 70,000 HIV HIV NA NA 360,000 360,000 Non Non-

  • HIV Severe

HIV Severe Immunodeficiency Immunodeficiency Total Total Non Non-

  • HIV Viral

HIV Viral Infection Infection (HBV) (HBV) Secondary Secondary Immunodeficiency Immunodeficiency Primary Primary Immunodeficiency Immunodeficiency Primary Primary Immunodeficiency Immunodeficiency 27.35 million 27.35 million 781,000 781,000 23.6 million 23.6 million 300,000 300,000 Developed Regions Developed Regions (Existing Carriers) (Existing Carriers) Developed Regions Developed Regions (New Cases Annually) (New Cases Annually) 2 million 2 million 51,000 51,000 Developed Regions Developed Regions (Prevalence) (Prevalence) Developed Regions Developed Regions (Incidence) (Incidence) Worldwide (1st World) market size

Potential sales Potential sales US $1.5b annually US $1.5b annually 150,000 potential 150,000 potential kit sales annually kit sales annually 780,000 potential 780,000 potential patients (1 patients (1st

st world)

world)

Kit Price Kit Price US $10,000 US $10,000

Source: Data derived from GLOBOCAN 2002 database: summary table (abstracts), International Agency for Research on Cancer (IARC) and CANCERMondial, Descriptive Epidemiology Group (DEP) of IARC and various others

T Cells

slide-19
SLIDE 19

Direct sales

Cell therapy business model Cell therapy business model

Phase I

(~10-20 patients)

Phase II

(~20-30 patients)

Indirect Sales Phase III

(~100-150 patients)

Production kits Pre-clinical

HIV Hepatitis Leukaemia

Stem cell transplants

Strategic Partners

Revenue

Prostate cancer Breast cancer Melanoma Herpes CMV EBV Blood disorders

Clinical trial stages Therapy areas

T Cells Expansion

slide-20
SLIDE 20
  • Exclusive & perpetual rights to matrix (non-orthopedic)
  • 4 patents issued

Stem cell matrix expansion Stem cell collagen expansion T cell production

  • 25 others pending

Stem cell expansion T cell production Spinner systems Multi-potent stem cells

Intellectual property Intellectual property

slide-21
SLIDE 21

Company financials Company financials (for 30

(for 30th

th June 2005)

June 2005)

1 Running rate (P&L account) refers to the average monthly loss from operations before depreciation of

fixed assets and amortisation of goodwill, patents and licenses.

$374,000 per month Cash burn (current)1 $13,724,000 Cash $12,521,000 Net tangible assets at 18.4 cents/share 68,000,000 Shares on issue $4,122,000 Consolidated revenue

slide-22
SLIDE 22

Next 6 months Next 6 months

T cell immunotherapy Phase I clinical trial initiated T cell immunotherapy T cell immunotherapy Phase I clinical trial initiated Revenue growth

  • Tissue Banking
  • Product Revenue

Revenue growth

  • Tissue Banking
  • Product Revenue

Stem cell expansion US / FDA IND filling Stem cell expansion Stem cell expansion US / FDA IND filling Market expansion

  • Australia
  • Asia
  • US
  • UK

Market expansion

  • Australia
  • Asia
  • US
  • UK
slide-23
SLIDE 23

Board & Management Board & Management

  • Mr. Christopher Fullerton (Chairman & Non Executive Director)
  • Mr. Christopher Fullerton (Chairman & Non Executive Director)

HCN, Standard Chartered, Asia Securities, HCN, Standard Chartered, Asia Securities, Schroders Schroders

  • Mr. Steven Fang (CEO, Executive Director)
  • Mr. Steven Fang (CEO, Executive Director)

Sterling Winthrop, Baxter and Becton Dickinson Sterling Winthrop, Baxter and Becton Dickinson

  • Mr. Ian Brown (COO, Executive Director)
  • Mr. Ian Brown (COO, Executive Director)

Chromogenix (previously Pharmacia), Helena Laboratories Chromogenix (previously Pharmacia), Helena Laboratories

  • Dr. Mark Pykett (Non Executive Director)
  • Dr. Mark Pykett (Non Executive Director)

University of Pennsylvania and Harvard University University of Pennsylvania and Harvard University

  • Dr. Anthony Soh (Non Executive Director)
  • Dr. Anthony Soh (Non Executive Director)

Havas Havas MediMedia MediMedia, UOB and APCM , UOB and APCM

  • Mrs. Eileen Tay (Non Executive Director)
  • Mrs. Eileen Tay (Non Executive Director)

KPMG, KPMG, MediaRing MediaRing

  • Mr. Jeremy Yee (CFO)
  • Mr. Jeremy Yee (CFO)

KPMG KPMG

slide-24
SLIDE 24

SAB SAB

Professor Bob Williamson Professor Bob Williamson AO, BSc (Hon), PhD, FAA, FRS AO, BSc (Hon), PhD, FAA, FRS Professor John Mackenzie Professor John Mackenzie AO, BSc (Hon), PhD, FASM, FACTM AO, BSc (Hon), PhD, FASM, FACTM Professor Professor Cees Cees Th.

  • Th. Smit

Smit Sibinga Sibinga MD, PhD, FRCP MD, PhD, FRCP Edin Edin, , FRCPath FRCPath Professor Ng Soon Professor Ng Soon Chye Chye MBBS, MBBS, MMed MMed, FRCOG, FAMS, MD , FRCOG, FAMS, MD Professor Low Cheng Hock Professor Low Cheng Hock MBBS, MMED, FRACS, FRCS(E), FAMS, PPA(E), PPA(P) MBBS, MMED, FRACS, FRCS(E), FAMS, PPA(E), PPA(P) Associate Professor Craig Jordan Associate Professor Craig Jordan BA, PhD BA, PhD Associate Professor Associate Professor Hanry Hanry Yu Yu BSc, MSc, PhD BSc, MSc, PhD Assistant Professor Assistant Professor Hutmacher Hutmacher, , Dietmar Dietmar Werner Werner M.Biomed.Eng M.Biomed.Eng, PhD, MBA , PhD, MBA

slide-25
SLIDE 25

Contact details Contact details

Steven Fang, CEO Mobile +61 (0)400 933 243 Email steven.fang@cygenics.com Ian Brown, COO Mobile +61 (0)438 565 212 Email ian.brown@cygenics.com Cygenics Limited Level 4, 414 Lonsdale St, Melbourne, Vic 3000, Australia Telephone +61 (0)3 9642 5580, Facsimile +61 (0)3 9642 5581 Web www.cygenics.com